There are also available data indicating a possible role of SYNE1 variants (although others than those shown in our study) in the development of CAD by their involvement in the morbidity of hypercholesterolemia and hypertriglyceridemia through gene–gene and SNP-SNP interactions [26]. This evidence concerns the gene SYNE1 and hypertriglyceridemia.